Last reviewed · How we verify

NCT03910426

Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients

Completed Last updated 3 May 2023
What this trial tests

trial testing Blood sampling in Dialysis in 216 participants. Completed in 31 December 2018.

Timeline
15 October 2015
Primary endpoint
31 December 2018
31 December 2018

Quick facts

Lead sponsorUniversity Hospital, Ghent
StatusCompleted
Study typeOBSERVATIONAL
Enrollment216
Start date15 October 2015
Primary completion31 December 2018
Estimated completion31 December 2018

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Ghent

Who can join

18 and older, any sex, with Dialysis or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with end-stage kidney disease are treated with dialysis to increase their life expectancy as well as their quality of life (QoL). Scientific researchers are currently still looking for markers to evaluate dialysis in an objective way. It has been proven before that the currently clinically used parameters (like the dialysis adequacy parameter Kt/V) are not appropriate enough to estimate dialysis dose. The current project aims at identifying potential (predicting) biomarkers based on functional capacity, nutritional status and/or QoL.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Associations between the measures of physical function, risk of falls and the quality of life in haemodialysis patients: a cross-sectional study.
    Vanden Wyngaert K, Van Craenenbroeck AH, Eloot S, Calders P, et al · · 2020 · cited 22× · PMID 31906987 · DOI 10.1186/s12882-019-1671-9
  2. The complexity of sleep disorders in dialysis patients.
    Eloot S, Holvoet E, Dequidt C, Maertens SJ, et al · · 2021 · cited 19× · PMID 34476089 · DOI 10.1093/ckj/sfaa258
  3. The importance of physical performance in the assessment of patients on haemodialysis: A survival analysis.
    Vanden Wyngaert K, Van Biesen W, Eloot S, Van Craenenbroeck AH, et al · · 2022 · cited 10× · PMID 35588129 · DOI 10.1371/journal.pone.0268115
  4. Markers of protein-energy wasting and physical performance in haemodialysis patients: A cross-sectional study.
    Vanden Wyngaert K, Celie B, Calders P, Eloot S, et al · · 2020 · cited 6× · PMID 32730305 · DOI 10.1371/journal.pone.0236816
  5. Composite Uremic Load and Physical Performance in Hemodialysis Patients: A Cross-Sectional Study.
    Vanden Wyngaert K, Van Craenenbroeck AH, Holvoet E, Calders P, et al · · 2020 · cited 6× · PMID 32098304 · DOI 10.3390/toxins12020135

Verify or expand the search:

Other trials of Blood sampling

Trials testing the same drug.

Other recruiting trials for Dialysis

Currently open trials in the same condition.

Other University Hospital, Ghent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03910426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing